Special Issue on Aryl hydrocarbon receptor (AHR) in carcinogenesis, tumor suppression and cancer immunotherapy

Guest editors:
Fei Chen, PhD, Professor
Stony Brook Cancer Center
Stony Brook University

Email:

AHR is oncogenic but also tumor suppressive in a context dependent manner. In addition to functioning as a master regulator for the transcription of the major detoxification enzymes, AHR is important for the expression of a wide spectrum of pro-oncogenic and tumor suppressor genes. The involvement of AHR in the lineage development and functional specialization of the innate and adaptive immune cells, such as NK cells, macrophages, T regulatory cells (Treg), and T helper 17 (Th17 cells), enables AHR as a critical player in inflammation and immunotherapy of the tumors. Despite considerable progression in characterizing AHR and the AHR signaling, a systemic assessment on the mechanisms of AHR contribution to human cancers is currently lacking. Accordingly, this proposed thematic issue will not only provide an in-depth view on the roles of AHR played in cancer initiation, progression, and metastasis, but also yield new insights into the designs of conventional and immunotherapy of cancers.

Authors should prepare their manuscripts in MS Word according to http://www.ijbs.com/ms/author and submit them at http://www.ijbs.com/ms/submit (select the guest editor as one of the "Suggested reviewers" and mark "Aryl hydrocarbon receptor (AHR) Special Issue" in his affliation field to identify the paper).

Schedule
Manuscript due: 2023-9-1

Tentative publication date: 2024-1-1

Detailed formatting instructions, in particular, the formatting of references, can be found in http://www.ijbs.com/ms/author.